FDA approves Taclonex Scalp for psoriasis

Warner Chilcott and LEO Pharma have received FDA approval for Taclonex Scalp (calcipotriene 0.005% and betamethasone dipropionate 0.064% topical suspension), a once-daily therapy for the treatment of moderate-to-severe psoriasis vulgaris of the scalp in adults.

Taclonex Ointment is already available for the topical treatment of psoriasis vulgaris in adults.

For more information call (800) 521-8813 or visit www.taclonex.com.